Summit Therapeutics (SMMT) Leases (2019 - 2025)
Summit Therapeutics (SMMT) has disclosed Leases for 7 consecutive years, with $5.4 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Leases fell 32.05% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Sep 2025, down 32.05%, and an annual FY2024 reading of $7.1 million, up 21.93% over the prior year.
- Leases was $5.4 million for Q3 2025 at Summit Therapeutics, down from $5.6 million in the prior quarter.
- Across five years, Leases topped out at $9.4 million in Q1 2024 and bottomed at $1.5 million in Q1 2021.
- Average Leases over 5 years is $5.0 million, with a median of $5.4 million recorded in 2025.
- The sharpest move saw Leases surged 403.61% in 2021, then crashed 36.3% in 2025.
- Year by year, Leases stood at $2.8 million in 2021, then skyrocketed by 49.64% to $4.2 million in 2022, then surged by 40.34% to $5.9 million in 2023, then rose by 21.93% to $7.1 million in 2024, then decreased by 24.13% to $5.4 million in 2025.
- Business Quant data shows Leases for SMMT at $5.4 million in Q3 2025, $5.6 million in Q2 2025, and $6.4 million in Q1 2025.